Valuation: GENFIT

Market Cap 551M 618M 507M 460M 873M 57.9B 894M 6.07B 2.42B 31B 2.32B 2.27B 97.63B P/E 2026 *
-13.8x
P/E 2027 * 13.3x
Enterprise Value 598M 670M 551M 500M 947M 62.83B 971M 6.59B 2.63B 33.64B 2.52B 2.46B 106B EV / Sales 2026 *
7.11x
EV / Sales 2027 * 2.79x
Free-Float
86.79%
Yield 2026 *
-
Yield 2027 * -
1 day-2.18%
1 week-2.71%
Current month-0.74%
1 month+28.18%
3 months-18.58%
6 months+21.67%
Current year+104.75%
1 week 10.02
Extreme 10.02
11.6
1 month 7.72
Extreme 7.72
11.72
Current year 5.05
Extreme 5.05
15.48
1 year 3.58
Extreme 3.58
15.48
3 years 2.62
Extreme 2.62
15.48
5 years 2.62
Extreme 2.62
15.48
10 years 2.62
Extreme 2.62
35.65
Manager TitleAgeSince
Chief Executive Officer 58 16/09/2019
Director of Finance/CFO 52 22/04/2021
Chief Tech/Sci/R&D Officer - 27/11/2025
Director TitleAgeSince
Chairman 70 16/06/2017
Director/Board Member 58 16/06/2017
Director/Board Member 70 16/06/2017
Date Insider Type Main position Quantity % Market Cap. Importance
5/3/26 Exercice

Chief Operating Officer

11,250 0.0225%
5/3/26 Exercice

Chief Operating Officer

7,083 0.0142%
5/3/26 Sell

Chief Operating Officer

7,083 0.0142%
Change 5-day change 1-year change 3-year change Capi.($)
-2.18%-2.71%+197.30%+252.86% 618M
+2.24%+8.40%+58.47%+69.00% 68.22B
+0.80%+9.10%+15.49%+89.43% 59.82B
+0.12%+1.50%+23.97%+97.85% 56.07B
+2.55%+15.52%+30.43%+120.17% 47.67B
+2.58%+7.89%+32.49%+45.30% 45.95B
+4.09%+6.37%+228.06%+899.75% 43.29B
-0.47%+9.38%+27.53%+52.40% 35.66B
-0.07%-1.37%+95.57%+70.37% 34.73B
+1.48%+6.21%-38.80%+395.73% 25.47B
Average +0.85%+7.33%+67.05%+209.29% 42B
Weighted average by Cap. +1.37%+7.83%+53.92%+184.08%

Financials

2026 *2027 *
Net sales 84.16M 94.29M 77.44M 70.29M 133M 8.84B 137M 926M 369M 4.73B 354M 346M 14.9B 148M 166M 136M 124M 234M 15.54B 240M 1.63B 649M 8.32B 622M 609M 26.2B
Net income -40.2M -45.04M -36.99M -33.57M -63.63M -4.22B -65.2M -443M -176M -2.26B -169M -165M -7.12B 72.41M 81.12M 66.63M 60.47M 115M 7.6B 117M 797M 318M 4.07B 304M 298M 12.82B
Net Debt 46.99M 52.65M 43.24M 39.24M 74.37M 4.93B 76.22M 517M 206M 2.64B 198M 193M 8.32B -138M -155M -127M -115M -219M -14.51B -224M -1.52B -606M -7.77B -581M -569M -24.47B
Projected Income Statement - Annual - GENFIT
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
180
Date Price Change Volume
11/11/26 EUR 10.78 -2.18% 168,752
09/11/26 EUR 11.02 +3.96% 283,855
06/11/26 EUR 10.60 -7.34% 518,050
05/11/26 EUR 11.44 +2.69% 266,012
04/11/26 EUR 11.14 +0.54% 247,594
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - GENFIT
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
11.02EUR
Average target price
21.30EUR
Spread / Average Target
+93.28%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - GENFIT
  1. Stock Market
  2. Stocks
  3. GNFT Stock